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T follicular helper (TFH) and T helper 1 (Th1) cells
generated after viral infections are critical for the
control of infection and the development of immuno-
logical memory. However, the mechanisms that
govern the differentiation and maintenance of these
two distinct lineages during viral infection remain un-
clear. We found that viral-specific TFH and Th1 cells
showed reciprocal expression of the transcriptions
factors TCF1 and Blimp1 early after infection, even
before the differential expression of the canonical
TFH marker CXCR5. Furthermore, TCF1 was intrinsi-
cally required for the TFH cell response to viral infec-
tion; in the absence of TCF1, the TFH cell response
was severely compromised, and the remaining
TCF1-deficient TFH cells failed to maintain TFH-asso-
ciated transcriptional and metabolic signatures,
which were distinct from those in Th1 cells. Mecha-
nistically, TCF1 functioned through forming negative
feedback loops with IL-2 and Blimp1. Our findings
demonstrate an essential role of TCF1 in TFH cell re-
sponses to viral infection.
INTRODUCTION
CD4 T cells constitute an essential force of the adaptive immune
system and are critical for vaccination and immune responses
against infections and tumors. CD4 T cells modulate the immune
response through various mechanisms, including secretion of
cytokines and direct cell-cell interaction. Depending on the anti-
gen, microenvironment, and cytokine milieu, activated CD4
T cells can develop into distinct effector populations, each char-
acterized by unique effector functions and differentiation pro-
gramming (Crotty, 2011; Zhou et al., 2009). One major function
of CD4 T cells is to help the humoral immune response, a func-
tion that is carried out by a CD4 subset known as T follicular help-
er (TFH) cells (Cannons et al., 2013; Crotty, 2011). TFH cells
express a set of surface markers, such as CXCR5, which enableCell Repthem to migrate to the B cell follicle and distinguish them from
other CD4 subsets. TFH cells provide crucial help for the initiation
and maintenance of germinal centers (GCs), which are indis-
pensable for antibody affinity maturation and the development
of long-term humoral immunity conferred by long-lived plasma
cells and memory B cells (Victora and Nussenzweig, 2012). TFH
cells signal to antigen-presenting cognate B cells through the
secretion of cytokines, such as IL-4 and IL-21, as well as the
expression of CD40L and ICOS that engage their binding part-
ners on B cells (Crotty, 2011).
TFH cells express high levels of Bcl6, a transcriptional
repressor, which is essential for TFH cell differentiation (Johnston
et al., 2009; Nurieva et al., 2009; Yu et al., 2009a). In contrast,
Blimp1, an antagonist of Bcl6, is highly expressed by non-TFH
effector cells and suppresses TFH cell differentiation (Johnston
et al., 2009). Bcl6 expression is triggered in activated T cells early
after antigen exposure through the interaction between dendritic
cells (DCs) and T cells (Baumjohann et al., 2011; Choi et al.,
2011). After priming by DCs, TFH cells upregulate CXCR5, down-
regulate CCR7, and move to the T-B zone border where they
interact with cognate B cells (Allen et al., 2007; Baumjohann
et al., 2011; Haynes et al., 2007). TFH and pre-GC B cells then
migrate into the B cell follicle and initiate the GC reaction (Crotty,
2011). The interaction with cognate B cells is required for the
maintenance and expansion of TFH cells (Baumjohann et al.,
2011; Choi et al., 2011). In contrast, IL-2 signaling restricts the
TFH cell response via STAT5- and Blimp1-mediated pathways
(Ballesteros-Tato et al., 2012; Johnston et al., 2012). However,
despite recent progress on the regulation of TFH cell differentia-
tion, many molecular mechanisms involved in the initiation and
maintenance of TFH cells remain to be elucidated.
T cell factor 1 (TCF1) is a key transcription factor of the Wnt
signaling pathway, which activates Wnt target genes when
bound by b-catenin (Verbeek et al., 1995). Multiple TCF1 iso-
forms are produced as a result of alternative splicing and dual
promoter usage of the Tcf7 gene and can be grouped into long
and short isoforms having or lacking the b-catenin-binding
domain (Van deWetering et al., 1996). TCF1 is induced by Notch
signaling during T cell development and is highly expressed in
thymocytes and mature naive T cells (Xue and Zhao, 2012).
Various stages of T cell development, such as T cell lineageorts 12, 2099–2110, September 29, 2015 ª2015 The Authors 2099
Figure 1. TCF1 Is Differentially Expressed
between TFH and Th1 Cells after LCMV
Infection
(A and B) 106 CellTrace Violet-labeled (CTV) puri-
fied naive CD45.1+ Blimp1-YFP SMARTA CD4
T cells were transferred into C57BL/6 mice fol-
lowed by infection with LCMV Armstrong. Sple-
nocytes (gated on CD45.1+ SMARTA CD4 T cells)
were analyzed on days 1.5, 2, and 3 p.i.
(A) Analyses of Blimp1-YFP, CXCR5, and TCF1
expression are shown. (B) Analyses of CTV dilution
plus phenotypic markers are shown.
(C) C57BL/6 mice received 104 purified naive
CD45.1+ Blimp1-YFP SMARTA CD4 T cells and
were infected with LCMV Armstrong. Splenocytes
(gated on SMARTA cells) were analyzed on day 7
p.i. for Blimp1-YFP, CXCR5, and TCF1. (Right)
TCF1 in SMARTA cells (blue) and host B cells (red)
is shown.
(D) TCF1 protein in day 3 TFH (CXCR5
highTim3low),
day3Th1 (CXCR5lowTim3high), day8TFH (CXCR5
high
SLAMlow), and day 8 Th1 (CXCR5lowSLAMhigh)
SMARTACD4T cells.b-actinwas used as a loading
control.
Data in (A) and (B) are from a single experiment (nR 2 per time point), representative of more than four independent experiments. Data in (C) are from a single
experiment (n = 3) representative of two independent experiments. Western blots are representative of two independent experiments.commitment of hematopoietic progenitor cells, b selection, and
development from double-negative (DN) to double-positive (DP)
thymocytes, are regulated by TCF1 (Germar et al., 2011; Oka-
mura et al., 1998; Weber et al., 2011; Yu et al., 2012). During
the CD8 T cell response, TCF1 is required for the development
of central memory CD8 T cells and optimal recall response by
memory cells (Zhou et al., 2010). In CD4 T cells, TCF1 promotes
Th2 differentiation by inducing GATA3 expression and restricts
IFNg expression by T helper 1 (Th1) cells (Yu et al., 2009b). How-
ever, the role of TCF1 in the TFH cell differentiation is still
unknown.
In this study, we found that, very early after viral infection,
effector CD4 T cells differentiate into TCF1highBlimp1low TFH
and TCF1lowBlimp1high Th1 cells. Notably, Tcf7 deficiency led
to a T-cell-intrinsic defect in viral-specific TFH cell responses,
associated with decreased TFH cells and reduced GCs. Mecha-
nistically, we found that TCF1 is required for the generation and
maintenance of distinct transcriptional and metabolic signatures
of TFH cells, including repression of Il2ra and Prdm1, the gene
products of which limit TFH cell responses. Together, our data
demonstrate that TCF1 is essential for the anti-viral TFH cell
response.
RESULTS
Viral-Specific Effector CD4 T Cells Can Be Separated
into TCF1highBlimp1low TFH and TCF1
lowBlimp1high Th1
Cells
During viral and intracellular bacterial infections, effector CD4
T cells can be divided into CXCR5highBcl6high TFH and CXCR5
low
Blimp1high Th1 cells before the initiation of GCs (Choi et al., 2011,
2013; Pepper et al., 2011). However, it remains unclear how early
these two lineages start to diverge. To address this, we used
SMARTA CD4 T cells, which express a transgenic T cell receptor2100 Cell Reports 12, 2099–2110, September 29, 2015 ª2015 The A(TCR) that recognizes the GP66-77 epitope on lymphocytic cho-
riomeningitis virus (LCMV), crossed to a Blimp1-YFP reporter to
track Blimp1 expression during the response to LCMV (Fooks-
man et al., 2014; Oxenius et al., 1998). Strikingly, bimodal
expression of Blimp1 was observed as early as day 1.5 post-
infection (p.i.) (Figures 1A, S1A, and S1B), when SMARTA cells
had only undergone the first few cell divisions (Figure 1B). Inter-
estingly, at this early time point, CXCR5 was expressed by both
Blimp1high and Blimp1low cells (Figure 1A). However, after day 2
p.i., Blimp1high SMARTA cells started to express lower levels of
CXCR5 than their Blimp1low counterparts (Figures 1A and
S1B). Accordingly, analysis of splenic sections from mice trans-
ferred with Blimp1-YFP reporter SMARTA cells revealed that
both TFH (Blimp1
low) and Th1 (Blimp1high) SMARTA cells could
be found in splenic B cell follicles on day 2 p.i. (Figure S1D). In
contrast, by day 3 p.i., most SMARTA cells in B cell follicles
were Blimp1low TFH cells, consistent with the lower expression
of CXCR5 in Th1 cells (Figure S1E).
To further characterize the differentiation program of early TFH
and Th1 cells, we looked for transcription factors that were differ-
entially expressed between these cells. Based on our unpub-
lished RNA sequencing studies and previously published data
(Choi et al., 2013), TFH cells express much higher levels of Tcf7
transcripts than their Th1 counterparts. To evaluate this further,
we analyzed the kinetics of expression of TCF1, the protein en-
coded by Tcf7, at a single-cell level early after LCMV infection
by flow cytometry (Figures 1A, 1B, S1A, and S1C). SMARTA
T cells could be readily separated into TCF1high and TCF1low
populations starting from day 2 p.i., likely as a result of the
gradual downregulation of TCF1 (which is expressed in naive
cells) in a subset of SMARTA cells (Figures 1A and S1A). Notably,
whereas TCF1high SMARTA cells maintained high CXCR5,
TCF1low SMARTA cells expressed less CXCR5 after day 2 p.i.
(Figures 1A and S1C). In addition, there was a clear inverseuthors
correlation between TCF1 and Blimp1, as well as a positive cor-
relation between TCF1 and Bcl6 (Figures 1A and S1F), suggest-
ing that TCF1 can be used to distinguish TFH cells from Th1 cells.
Indeed, TCF1high SMARTA cells were almost exclusively found in
the CXCR5highBlimp1low TFH subset, while TCF1
low cells were
primarily in the CXCR5lowBlimp1high Th1 subset (Figure S1G).
IL-2 signaling suppresses TFH development, and early Th1
cells express more CD25, the high-affinity IL-2 receptor, than
early TFH cells (Ballesteros-Tato et al., 2012; Choi et al., 2011;
Johnston et al., 2012; Pepper et al., 2011). We found that, while
most SMARTA cells showed substantial CD25 expression on
day 1.5 p.i., TCF1high TFH cells downregulated CD25much faster
than TCF1low Th1 cells (Figure S1F). We also found that expres-
sion of Tim3, a co-inhibitory receptor expressed by exhausted
CD8 T cells (Jin et al., 2010; Sakuishi et al., 2010), correlated
well with Blimp1 (Figure S1F). We, therefore, used Tim3 as an
early Th1 marker when the Blimp1-YFP reporter was not
available.
To determine whether the dichotomy of Blimp1 and TCF1
expression between TFH and Th1 cells was maintained later dur-
ing infection when TFH cell responses rely on antigen presenta-
tion by GC B cells (Baumjohann et al., 2011; Choi et al., 2011),
we examined their expression in SMARTA cells 1 week after
LCMV infection. As expected, CXCR5high TFH cells mostly ex-
pressed low levels of Blimp1 (Figures 1C and S1H) and SLAM
(Figure S1I; Johnston et al., 2009). Strikingly, TCF1 still nega-
tively correlated with Blimp1 expression; co-staining of TCF1
and Blimp1 clearly separated SMARTA into two populations
(Figures 1C and S1H). Furthermore, TCF1high cells were again
primarily in the CXCR5highBlimp1low TFH population, while the
CXCR5lowBlimp1high cells contained mostly TCF1low cells (Fig-
ure S1J) in which TCF staining was only slightly higher than
that in B cells, which do not express TCF1 (Staal and Clevers,
2000; Figure 1C). Tcf7 encodes multiple isoforms as a result of
alternative splicing and dual promoter usage (Van de Wetering
et al., 1996). The flow cytometry antibody we used binds to the
N-terminal b-catenin-binding domain and, therefore, only recog-
nizes the long isoforms. To further assess TCF1 expression, we
sorted TFH and Th1 SMARTA cells on day 3 p.i. and day 8 p.i.,
and we evaluated TCF1 protein levels by immunoblots using
an antibody that recognizes all isoforms. While TFH cells from
both time points expressed multiple isoforms with or without
the b-catenin-binding domain, expression of all TCF1 isoforms
was very low in Th1 cells, particularly on day 3 p.i. (Figure 1D).
Thus, TCF1 protein levels are high in TFH but low in Th1 cells in
both pre-GC phase and GC phase of the immune response to
LCMV.
Tcf7 Is Repressed by IL-2 and Blimp1
The bifurcation in Tcf7 expression between TFH and Th1 cells
prompted us to investigate which signals induce the loss of
Tcf7 in Th1 cells. IL-2 signaling suppresses TFH differentiation
and Bcl6 expression in activated CD4 T cells (Ballesteros-Tato
et al., 2012; Johnston et al., 2012; Oestreich et al., 2012). The
fact that TCF1low Th1 cells expressedmore CD25, the high-affin-
ity IL-2 receptor, than TCF1high TFH cells (Figure S1F) suggested
IL-2 might suppress Tcf7. To examine this possibility, we moni-
tored the effect of IL-2 on in-vitro-activated CD4 T cells. We stim-Cell Repulated CD4 T cells with anti-CD3ε and CD28 for 3 days, then
washed and cultured cells with or without IL-2 for 1 additional
day. CD4 T cells receiving IL-2 expressed higher surface
CD25, consistent with the role of IL-2 in promoting CD25 expres-
sion. Moreover, these cells expressed 50% less TCF1 than cells
cultured without IL-2 (Figure 2A). Thus, differential IL-2 signals
between TFH and Th1 cells may contribute to differences in
TCF1 levels.
A previous study suggested that IL-2 suppresses TFH differen-
tiation via Blimp1 (Johnston et al., 2012). The inverse correlation
between TCF1 and Blimp1 expression suggested that Blimp1
might also selectively repress the Tcf7 locus in Th1 cells. To
examine this possibility, we transduced SMARTA cells with
retroviral vectors expressing a scrambled small hairpin RNA
(shRNA) or shRNA targeting Prdm1, which encodes Blimp1,
and we analyzed the effect on TCF1 levels in Th1 cells. Knock-
down of Blimp1 caused an increase in TCF1 expression in
CXCR5lowCD25high Th1 SMARTA cells on day 3 p.i., compared
to untransduced or control-vector-transduced Th1 SMARTA
cells (Figure 2B). Interestingly, the region 30 kb upstream of
the Tcf7 transcription start site (TSS) (Figure S2) contains evolu-
tionarily conserved sequences with Blimp1-binding motifs
(GAAAG) (Kuo and Calame, 2004). This region is bound by
TCF1 itself, as well as other transcription factors based on pub-
lished chromatin immunoprecipitation sequencing (ChIP-seq)
data from different cell types, and has been shown to regulate
Tcf7 transcription (Germar et al., 2011; Steinke et al., 2014).
Indeed, using ChIP assays, we found that Blimp1 physically
interacted with this region in TFH and Th1 SMARTA cells (Fig-
ure 2C); however, the binding of Blimp1 was significantly stron-
ger in Th1 cells than in TFH cells, consistent with the different
abundance of Blimp1 in the two populations. We also observed
more H3 K4 trimethylation (H3K4me3), which is associated with
active transcription (Jenuwein and Allis, 2001), in this region in
TFH cells than in Th1 cells, while more H3 K27 trimethylation
(H3K27me3), which is linked to transcriptional repression (Cao
et al., 2002), was found in Th1 cells than in TFH cells (Figure 2D).
Furthermore, the 30-kb region increased luciferase activity
2-fold relative to a control luciferase construct; however, overex-
pression of Blimp1 repressed the enhancer activity of this region
(Figure 2E). Thus, Blimp1 may suppress Tcf7 expression in
Th1 cells.
Tcf7 Deficiency Causes a Severe Defect in the TFH Cell
Response to LCMV
The high expression of TCF1 in TFH cells suggested a potential
role of TCF1 in TFH cell development. Tcf7 is a key player in mul-
tiple steps during T cell development (Verbeek et al., 1995;
Weber et al., 2011). To study the immune response of mature
T cells, we bred mice carrying a conditional Tcf7 allele to CD4-
Cre mice, which initiate Cre activity in DP thymocytes (Steinke
et al., 2014), to generate Tcf7 conditional (cKO) mice. Cre-medi-
ated deletion caused more than a 10-fold reduction in TCF1 in
CD4 T cells (Figure S3A). Although naive cKO mice had lower
CD4 T cell frequencies than wild-type (WT) controls, frequencies
of CD44high CD4 T cells were comparable (Figure S3B). We then
infected cKO andWTmice with LCMV and analyzed LCMV-spe-
cific CD4 T cell responses using theGP66-77 IAb tetramer on dayorts 12, 2099–2110, September 29, 2015 ª2015 The Authors 2101
Figure 2. IL-2 and Blimp1 Negatively Regu-
late TCF1 Expression
(A) Naive CD4 T cells were stimulated with anti-
CD3 and anti-CD28 for 3 days and then
cultured with or without IL-2 for 1 day, and the
mean fluorescence intensity (MFI) of CD25 and
TCF1 was determined by flow cytometry. Un-
paired Student’s t tests were performed; error
bars represent SD. Data are from a single
experiment representative of four independent
experiments.
(B) 106 SMARTA CD4 T cells were transduced
with retroviruses containing a scrambled control
sequence or shRNA for Prdm1 and transferred
into C57BL/6 recipients followed by infection
with LCMV. On day 3 p.i., TCF1 expression in
Th1 (CXCR5lowCD25high) SMARTA cells was
determined. Paired Student’s t tests were per-
formed between transduced (GFP+) and un-
transduced populations within each group. Each
line represents data from one individual mouse.
Data are from a single experiment (n = 4 per
group) representative of two independent ex-
periments.
(C and D) On day 8 p.i., TFH and Th1 SMARTA T cells were isolated, and ChIP assays were performed with antibodies to Blimp-1 (C) or a control IgG and with
antibodies to modified histone H3 (D) as indicated. ChIPs were amplified by qRT-PCR for the indicated region. Data are the mean ± SEM of three independent
experiments. Significance was determined by an unpaired t test.
(E) 293T cells were co-transfected with pGL3 SV40 promoter vector containing Tcf7 30-kb region and MSCV-IRES-GFP (MIG) with or without Blimp1.
Luciferase activity was normalized to Renilla activity and adjusted to the fold increase over empty pGL3 SV40 vector. Data are the mean ± SD of three inde-
pendent transfections in one of two independent experiments. Significance was determined by an unpaired t test.10 p.i. We used CXCR5, PD1, and Bcl6 to stain TFH cells and
SLAM to stain Th1 cells. While the ratio of CXCR5highSLAMlow
TFH to CXCR5
lowSLAMhigh Th1 tetramer+ CD4 T cells was close
to 1 inWTmice, the frequency of TFH cells among tetramer
+ cells
in cKO mice was markedly decreased (Figure 3A). We also
observed a substantial loss of tetramer+ CXCR5highPD1high and
CXCR5highBcl6high GC-TFH populations in cKO mice. Accord-
ingly, the number of GP66-77-specific TFH cells in the spleens
of cKO mice was reduced more than 6-fold (Figure 3B). In
contrast, the numbers of GP66-77-specific Th1 cells were not
significantly different between cKO and WT mice. TCF1 levels
in GP66-77-specific CD4 T cells were substantially decreased,
even in the remaining CXCR5+ TFH cells, suggesting that the
small fraction of TFH cells in cKO mice was not likely caused by
incomplete recombination (Figure S3C). Moreover, defective
TFH cell responses in cKO mice were not unique to one epitope,
as the frequencies of TFH cells among total CD44
high CD4 T cells
and total TFH counts in cKO spleens also were reduced (Fig-
ure 3C). Consistent with the role of TFH cells in supporting humor-
al responses and GC formation (Crotty, 2011), the numbers of
GC (GL7highFAShigh) B cells and activated (IgDlowFAShigh) B cells
in the cKO mice were less than half of those in WT mice
(Figure 3D).
To rule out that loss of TCF1 during thymocyte development
compromised TFH differentiation in cKO mice, we crossed the
conditional Tcf7 to ERT2-Cremice, which activate Cre by tamox-
ifen treatment (Seibler et al., 2003). By treating the inducible Tcf7
knockout mice (iKO) with tamoxifen for several days immediately
prior to LCMV infection, we ensured that iKO T cells had under-
gone thymic development similar to their ERT2-Creneg counter-2102 Cell Reports 12, 2099–2110, September 29, 2015 ª2015 The Aparts (data not shown). Similar to cKO mice, TFH cell responses
in tamoxifen-treated iKO mice on day 10 p.i. were severely
compromised compared to vehicle-treated counterparts, con-
firming that Tcf7 is critical for TFH cell responses during LCMV
infection (Figure 3E).
TFH Cells Require TCF1 in a CD4 T-Cell-Autonomous
Manner
In the above experiments, TCF1 was deleted in both CD4 and
CD8 T cells in cKO and iKO mice. To determine whether defec-
tive TFH cell responses in Tcf7 KO mice were intrinsic to CD4
T cells, we crossed Tcf7 cKO mice to SMARTA mice. Congeni-
cally marked naive CD4 T cells from WT and cKO SMARTA
mice were isolated, mixed at 1:1 ratios, and adoptively trans-
ferred to WT CD45.1 mice, which were subsequently infected
with LCMV (Figure 4A). By mixing WT and cKO SMARTA cells,
we could compare the two within each recipient exposed to the
same exact conditions and determine their phenotype with
higher accuracy and sensitivity. TFH cell differentiation involves
an early B-cell-independent phase and a subsequent B-cell-
dependent phase (Baumjohann et al., 2011; Choi et al.,
2011). To investigate the impact of Tcf7 deficiency on each
phase of TFH differentiation, we monitored CD4 T cell re-
sponses on days 3 and 8 p.i. On day 3 p.i., loss of TCF1 pref-
erentially reduced TFH cell responses as evidenced by the
decreased frequencies of CXCR5highTim3low as well as
CXCR5highBcl6high cells among cKO SMARTA cells (Figures
4B, 4C, and S4B). Tcf7 deficiency also caused a reduction in
the number of TFH (CXCR5
highTim3low) SMARTA cells and, to
a lesser extent, the number of Th1 (CXCR5lowTim3high)uthors
Figure 3. TCF1 Is Required for the Differen-
tiation of TFH Cells
(A–D) Tcf7loxP/loxP; CD4-Cre (cKO) mice and litter-
mate controls (WT) were infected with LCMV and
splenocytes isolated on day 10 p.i. (A) Analyses of
CXCR5, SLAM, PD1, and Bcl6 in WT and cKO
GP66-77 IAb tetramer+ CD4 T cells are shown. (B)
Numbers of GP66-77 IAb tetramer+ CXCR5high
SLAMlow (TFH) and CXCR5
lowSLAMhigh (Th1) CD4
T cells in spleens ofWT or cKOmice are shown. (C)
Representative fluorescence-activated cell sorting
(FACS) plots of CXCR5 and SLAM staining (gated
on CD44high CD4 T cells) and numbers of
CXCR5highSLAMlowCD44high (TFH) CD4 T cells in
spleens are shown. (D) Representative FACS plots
and numbers of FAShighGL7high (GC) B cells (gated
on CD19+B220+ cells) and activated (IgDlow
FAShigh) B cells in WT and cKO spleens are shown.
(E) Tcf7loxP/loxP; ERT2-Cre (iKO) mice were treated
with either 2 mg tamoxifen or vehicle daily for
3 days and then infected with LCMV. Day 10 p.i.
analyses of CXCR5 and SLAM staining (gated on
GP66-77 IAb tetramer+ CD4 T cells) and numbers
of GP66-77 IAb tetramer+ CXCR5highSLAMlow (TFH)
and CXCR5lowSLAMhigh (Th1) CD4 T cells in the
spleens are shown.
Data in (A)–(D) are from a single experiment (n = 4
per genotype) representing two independent ex-
periments. Data in (E) are from a single experiment
(n = 4 per genotype) representative of three inde-
pendent experiments. Significance was deter-
mined by unpaired t tests; error bars represent SD.SMARTA cells (Figure S4C). We then monitored the differentia-
tion of SMARTA cells at the peak of the immune response (day
8 p.i.) and observed an even more profound loss of TFH cells
in cKO SMARTA cells compared to that on day 3 p.i. The fre-
quencies of CXCR5highSLAMlow cells (Figure 4D) and
CXCR5highBcl6high cells (Figures 4E and S4E) were 4- to 5-
fold lower in cKO cells than those in their WT counterparts.
Similarly, there was close to a 10-fold reduction in the numbers
of cKO TFH SMARTA cells compared to those of WT, yet no sig-
nificant difference between the numbers of cKO and WT Th1
cells (Figure S4F).
To delete TCF1 only in naive SMARTA cells, we generated
Tcf7 iKO SMARTA mice and transferred mixed naive SMARTA
CD4 T cells from iKO SMARTA mice and their ERT2-Cre coun-
terparts (WT SMARTA) toWT recipients, which thenwere treated
with tamoxifen followed by LCMV infection. Similar to cKOCell Reports 12, 2099–2110, SepSMARTA cells, induced deletion of TCF1
preferentially affected TFH responses.
Both the frequencies and numbers of
TFH (CXCR5
highTim3low or CXCR5high
Bcl6high) iKO SMARTA cells on day 3 p.i.
were lower than their WT counterparts
(Figures S4H–S4J). Again, on day 8 p.i.,
we observed greater reductions in the fre-
quencies and numbers of TFH (CXCR5
high
SLAMlow or CXCR5highBcl6high) cells (Fig-
ures 4F, 4G, and S4L) within the iKOSMARTA population, yet Th1 cell numbers were more similar to
WT (Figure S4M). Together, our results demonstrate a cell-
intrinsic requirement forTCF1 for viral-specificTFHcell responses.
Finally, to further evaluate the capacity of Tcf7-deficient CD4
T cells to support humoral responses, we adoptively transferred
equal numbers of WT or iKO SMARTA CD4 T cells separately
into SAP KO mice, which cannot generate GC responses
because of defects in CD4 help (Crotty et al., 2003; Qi et al.,
2008), treated the chimeras with tamoxifen, and then infected
them with LCMV. On day 11 p.i., B cell responses were deter-
mined by the numbers of GC (GL7highFAShigh) and activated
(IgDlowFAShigh) B cells. In SAP KO mice that received iKO
SMARTA cells, the numbers of both GC and activated B cells
were lower than in those that received WT cells (Figure 4H).
Thus, T-cell-intrinsic defects caused by the loss of TCF1 led to
a compromised humoral response.tember 29, 2015 ª2015 The Authors 2103
Figure 4. Loss of TCF1 Causes a Cell-
Intrinsic Defect in TFH Cell Differentiation
Early after Infection
(A–E) As shown in the schematic (A), purified CD4
T cells from cKO (CD45.1CD45.2+) and WT
(CD45.1+CD45.2+) SMARTA mice were mixed at
1:1 ratio and transferred into WT CD45.1 mice
(106 cells per recipient for day 3 and 104 cells for
day 8 experiments). Chimeras were then infected
with LCMV. TCF1 deletion was confirmed by flow
cytometry (Figures S4A and S4D). Data are from a
single experiment (n = 4) representative of three
independent experiments. Each line represents
data from one mouse. (B and C) Frequencies of
TFH (CXCR5
highTim3low or CXCR5highBcl6high) and
Th1 (CXCR5lowTim3high) cells in WT and cKO
SMARTA cells in spleens on day 3 p.i. are shown.
(DandE) Frequenciesof TFH (CXCR5
highSLAMlowor
CXCR5highBcl6high) and Th1 (CXCR5lowSLAMhigh)
cells in splenicWTandcKOSMARTAcells on day 8
p.i. are shown.
(F and G) Purified CD4 T cells from iKO
(CD45.1CD45.2+) and WT (CD45.1+CD45.2+)
SMARTA mice were mixed at 1:1 ratio and
transferred into WT CD45.1 mice, which were then
treated with 2 mg tamoxifen for 3 days. Chimeras
were infectedwith LCMVandanalyzedon 8dayp.i.
for TCF1 (Figure S4K) and for frequencies of TFH
(CXCR5highSLAMlow or CXCR5highBcl6high) and Th1
(CXCR5lowSLAMhigh) cells in WT and iKO SMARTA
cells. Data are from a single experiment (n = 4)
representative of three independent experiments.
Each line represents data from one mouse.
(H) SAP KO (CD45.2) mice were transferred with
5,000 purified CD4 T cells from iKO or WT
SMARTA (CD45.2+) mice, treated with 2 mg
tamoxifen daily for 3 days, and infected with
LCMV, and splenocytes were stained for GC
(GL7highFAShigh) B cells and activated (IgDlow
FAShigh) B cells on day 11 p.i. Flow plots were
gated on CD19+B220+ cells. Data are from a single
experiment (n = 4) representative of three inde-
pendent experiments. Statistical significance was
determined by paired (B–G) or unpaired (H) t tests;
error bars represent SD.Tcf7 Deficiency Directly Compromises TFH Cell
Expansion
To determine how Tcf7 deficiency affects TFH cells, we exam-
ined the proliferative capacity of cKO SMARTA cells, as deter-
mined by their incorporation of bromodeoxyuridine (BrdU).
Interestingly, loss of TCF1 caused a reduction in BrdU incor-
poration in TFH, but not Th1, cKO SMARTA cells on day 5
p.i., at the middle of the clonal expansion phase (Figure S4N).
Moreover, cKO TFH cells showed slightly stronger annexin V
staining than their WT counterparts, suggesting that cKO TFH
cells may be more prone to apoptosis (Figure S4O). To directly
compare the ability of Tcf7-deficient and -sufficient TFH cells to2104 Cell Reports 12, 2099–2110, September 29, 2015 ª2015 The Aexpand, we sorted WT and iKO TFH (CXCR5
highTim3low) and
Th1 (CXCR5lowTim3high) SMARTA cells on day 3 p.i., mixed
equal numbers of WT and iKO TFH or WT and iKO Th1
SMARTA cells, and transferred the mixed TFH or Th1 cells
into infection-matched recipients. Four days post-transfer
(day 7 p.i.), 80% of the progeny from both WT and iKO donor
TFH cells stayed as TFH cells (CXCR5
highSLAMlow), while a
slightly higher percentage of progeny from iKO donor Th1 cells
stayed as Th1 cells than those from WT donor Th1 cells (Fig-
ures S4P and S4Q). However, the numbers of progeny from
iKO donor TFH cells were only half the numbers from WT donor
TFH cells, suggesting that Tcf7 deficiency indeed compromiseduthors
Figure 5. Loss of TCF1 Changes the Tran-
scriptional and Metabolic Signatures of TFH
Cells
(A) Microarray analyses of day 8 TFH (CXCR5
high
SLAMlow) and Th1 (CXCR5lowSLAMhigh) cKO and
WT SMARTA cells isolated by cell sorting from co-
transfer experiments set up as in Figure 4A. Genes
expressed >2-fold (p < 0.05) in WT TFH cells than in
WT Th1 cells were listed as the TFH gene set and
those > 2-fold (p < 0.05) expressed in WT Th1 cells
were listed as the Th1 gene set (Table S1).
Enrichment of gene sets in cKO relative to WT TFH
cells were determined by GSEA. Positive enrich-
ment scores (ESs) indicate enrichment in cKO TFH
cells; negative ESs indicate enrichment in WT TFH
cells.
(B) Enrichment of gene sets related to branched-
chain amino acid degradation, fatty acid meta-
bolism, and citrate cycle in cKO TFH relative to WT
TFH cells determined by GSEA using KEGG-
curated pathway database is shown.
(C–F) Experiments were set up as in Figure 4A. (C)
Comparison of mitochondrial mass between day 8
WT TFH (CXCR5
highSLAMlow, solid line) and WT
Th1 (CXCR5lowSLAMhigh, shaded) SMARTA cells,
as determined by MitoTracker Green FM, is
shown. (D) Mitochondrial mass of day 8 TFH and
Th1 cKO (red) and WT (blue) SMARTA cells is
shown. (E) Mitochondrial membrane potential of
day 8 WT TFH (solid line) and WT Th1 (shaded)
SMARTA cells, as determined by the MFI of
DiOC6(3) staining, is shown. (F) Mitochondrial
membrane potential of day 8 TFH and Th1 cKO
(red) and WT (blue) SMARTA cells is shown. Data
in (C)–(F) are from single experiments (n = 5)
representative of two independent experiments.
Statistical significance in (C)–(F) was determined
by paired t tests. Each line represents data from a
single mouse.the expansion of the transferred TFH cells, likely as a result of
reduced proliferation and/or survival.
Transcriptomic Analyses of Tcf7-Deficient TFH and Th1
Cells
To gain further insights into the properties of Tcf7-deficient TFH
and Th1 cells as well as the molecular pathways regulated by
TCF1 in these cells, we set up adoptive transfers and infections
as described in Figure 4A, and we performed microarray experi-
ments to profile the transcriptomes of WT and cKO TFH and Th1
SMARTAcells sorted from the samemiceonday 8p.i. As thepro-
portion of TFH cells was much lower among cKO SMARTA cells
than theirWT counterparts, we compared the transcriptomesbe-
tween WT and cKO cells within the TFH or Th1 subset in order to
filter out genes that were differentially expressed simply due to
the reduced TFH:Th1 ratio caused by Tcf7 deficiency. We first
generated TFH and Th1 signature gene sets by listing genes that
wereR2-fold (p < 0.05)more expressed in day 8 p.i. WT TFH cells
than day 8 p.i. WT Th1 cells or vice versa (Table S1). Then, we
used gene set enrichment analysis (GSEA) (Subramanian et al.,
2005) to determine whether these signatures were enriched inCell RepcKOcells orWT cells. Strikingly, day 8 p.i. cKOSMARTATFH cells
exhibited reducedTFH gene expression signatures and increased
Th1 signatures compared to WT SMARTA TFH cells (Figure 5A).
To better understand pathways affected by Tcf7 deficiency,
we performed GSEA to compare the gene signatures of cKO
and WT TFH cells using the Kyoto Encyclopedia of Genes and
Genomes (KEGG) and reactome-curated pathway databases.
cKO TFH cells showed significantly reduced signatures related
to gene expression (e.g., basal transcription factors, spliceo-
some, and aminoacyl-tRNA biosynthesis), DNA repair (e.g.,
nucleotide excision repair), and cell cycle and metabolism
(e.g., valine, leucine, and isoleucine degradation; pentose phos-
phate pathway; fatty acid metabolism; and citrate cycle) (Tables
S2 and S3). The reduced signatures related to branched-chain
amino acid degradation, fatty acid degradation, and the citrate
cycle in cKO TFH cells (Figure 5B) prompted us to investigate
whether Tcf7 deficiency affected mitochondria in TFH cells. Us-
ing MitoTracker Green FM to quantify the mitochondrial mass
in SMARTA cells, we found that WT TFH cells had higher mito-
chondrial mass than WT Th1 cells (Figure 5C), suggesting there
were metabolic differences between Th1 and TFH cells. Notably,orts 12, 2099–2110, September 29, 2015 ª2015 The Authors 2105
Figure 6. TCF1 Suppresses the Expression
of Prdm1 and Il2ra
(A and B) qRT-PCR analyses of mRNA levels of
Prdm1 and Il2ra in sorted day 3 (A) or day 8 (B) TFH
and Th1 iKO andWT SMARTA cells, normalized to
the mRNA levels of Actb. Data are from a single
experiment representative of two independent
experiments, set up as in Figures 4F and S4G.
Statistical significance was determined by an un-
paired t test; error bars represent SD.
(C) 104 purified CD4 T cells from cKO (CD45.1
CD45.2+) and WT (CD45.1+CD45.2+) SMARTA
mice were mixed at 1:1 ratio and adoptively
transferred into each of the recipients, which were
then infected with LCMV. On day 5 p.i., spleno-
cytes were collected and cultured with or without
50 U/ml human rIL-2 for 20min at 37C, andMFI of
pSTAT5 in TFH cKO and WT SMARTA was deter-
mined. Data are from a single experiment (n = 5)
representative of two independent experiments.
Significance was determined by a paired t test.
(D) ChIP from day 8 TFH and Th1 SMARTA cells
using antibodies to TCF1 or control IgG and
amplified by qRT-PCR for the indicated regions
(the third intron of Prdm1, the first intron of
Il2ra, and 23 kb from Il2ra TSS). Data are the
mean ± SEM of three independent experiments.
Significance was determined by an unpaired
t test.we also observed that mitochondrial mass was reduced in cKO
SMARTA TFH cells and to a lesser extent in cKO SMARTA Th1
cells (Figure 5D). The intensity of DiOC6(3) staining in cells can
be used to measure mitochondrial membrane potential, an indi-
cator of mitochondrial function (Rottenberg and Wu, 1998).
Again, we found that WT TFH cells showed stronger DiOC6(3)
staining than WT Th1 cells (Figure 5E). However, both TFH and
Th1 cKO SMARTA cells showed less DiOC6(3) staining than their
WT counterparts (Figure 5F). Together, our data suggest that TFH
cells exhibit metabolic differences from Th1 cells and, further-
more, that Tcf7-deficient TFH cells lose these characteristic
properties of TFH cells. Thus, TCF1 appears to be required to
generate and/or maintain TFH identity during viral infection.
TCF1 Negatively Regulates the Expression of CD25 and
Blimp1
Among the genes upregulated in cKO TFH cells (Table S4) were
Prdm1 and Il2ra, which encode Blimp1 and CD25, two proteins2106 Cell Reports 12, 2099–2110, September 29, 2015 ª2015 The Authorsinvolved in pathways that suppress TFH
cell differentiation. qRT-PCR results
confirmed that Prdm1 and Il2ra tran-
scripts in Tcf7-deficient TFH cells were
higher than those in WT TFH cells on day
3 as well as day 8 p.i. (Figures 6A and
6B). The elevated Il2ra transcript and sur-
face CD25 levels (Figure S5A) in Tcf7-
deficient TFH cells suggested a potential
increase in IL-2 responsiveness. To
address this, we cultured WT and cKOSMARTA cells isolated on day 5 p.i. with or without IL-2 and
measured IL-2 signaling by staining phosphorylated STAT5
(pSTAT5). The pSTAT5 levels were higher in TFH cKO SMARTA
cells than in their WT counterparts (Figure 6C), indicating
elevated IL-2 signaling in TFH cKO cells.
Published TCF1ChIP-seq data fromboth thymocytes (Germar
et al., 2011) andmature CD8 T cells (Steinke et al., 2014) indicate
the presence of TCF1-binding peaks in the third intron of Prdm1
as well as the first intron of Il2ra and a region 23 kb upstream of
Il2ra TSS (Figures S5B–S5D); the region in the third intron of
Prdm1 has been shown to be important for Prdm1 expression
in other cell types (Tunyaplin et al., 2004). To test whether
TCF1 physically interacts with these regions in viral-specific
CD4 T cells, we performed TCF1 ChIP experiments on sorted
TFH and Th1 SMARTA cells. Strikingly, TCF1 bound strongly to
all three regions in TFH cells, but not in Th1 cells (Figure 6D).
Moreover, these TCF1-binding sites showed extensive
H3K27me3 modification, associated with transcriptional
Figure 7. Tcf7 Deficiency Is Rescued by
Bcl6 Overexpression
(A) cKO and WT SMARTA CD4 T cells were mixed
at1:1 ratio, transduced with retroviral constructs
overexpressing Bcl6, and transferred into WT
CD45.1 recipients (23 104 cells per recipient) that
were then infected with LCMV.
(B) Frequencies of TFH within WT or cKO SMARTA
cells untransduced or transduced with Bcl6 over-
expression construct on day 8 p.i. Data are from a
single experiment representative of two indepen-
dent experiments. Significancewas determined by
paired t tests.repression (Cao et al., 2002), in TFH cells, but not in Th1 cells (Fig-
ure S5E). Thus, TCF1 can bind Prdm1 and Il2ra in TFH cells, and
loss of TCF1 leads to abnormal upregulation of these genes in
TFH cells.
Rescue of Tcf7-Deficient Phenotype by Enforced
Expression of Bcl6
Our results show that TCF1 in TFH cells suppressed the expres-
sion of Prdm1 (Figure 6). Given that Blimp1, encoded by Prdm1,
can be antagonized by Bcl6 (Crotty, 2011), we reasoned that
overexpression of Bcl6 might rescue the defective TFH cell differ-
entiation caused by loss of TCF1. To test this hypothesis, we
overexpressed Bcl6 in WT or cKO SMARTA cells through retro-
viral transduction (Figure 7A). On day 8 p.i., enforced expression
of Bcl6 rectified the defective TFH cell differentiation in cKO
SMARTA cells, greatly increasing the TFH frequency of cKO
SMARTA cells (Figure 7B). Thus, TCF1 acts upstream of the
Bcl6-Blimp1 axis to regulate TFH cell responses.
DISCUSSION
Upon viral or intracellular bacterial infections, effector CD4
T cells differentiate into Th1 cells, which protect the host through
secreted cytokines such as IFNg and TNFa and/or direct lysis of
infected cells, and TFH cells, which provide help for B cell re-
sponses (Choi et al., 2011; Crotty, 2011; Pepper et al., 2011;
Swain et al., 2012). The differentiation of TFH and Th1 cells occurs
before GC initiation and depends on DC priming and ICOS-
ICOSL interactions between activated CD4 T cells and DCs
(Choi et al., 2011; Pepper et al., 2011). However, the molecular
mechanisms that govern and maintain the balance of these
two distinct subsets are still unclear. TCF1 is critical for thymic
T cell development as well as Th2 polarization and the develop-Cell Reports 12, 2099–2110, Sepment of memory CD8 T cells during im-
mune responses (Weber et al., 2011; Yu
et al., 2009b; Zhou et al., 2010). Here we
show that viral-specific TFH cells maintain
high levels of TCF1, while viral-specific
Th1 cells downregulate TCF1 early after
infection. We further demonstrate that
both IL-2 and Blimp1 lead to TCF1 down-
regulation. Importantly, TCF1 was intrin-
sically required for robust antiviral TFH
cell responses as well as T cell help to B cells; in the absence
of TCF1, we observed decreased numbers of TFH cells and GC
B cells, and the remaining Tcf7-deficient TFH cells exhibited
reduced TFH cell transcriptional and metabolic signatures. We
provide evidence that TCF1 also acts upstream of the Blimp1-
Bcl6 axis and suppresses expression of both Prdm1 and Il2ra,
the products of which suppress TFH differentiation.
Previous studies have shown that induction of Bcl6 and
CXCR5 is associated with early TFH cells, while upregulation
of Blimp1 and CD25 is associated with early Th1 cells (Baum-
johann et al., 2011; Choi et al., 2011; Pepper et al., 2011).
However, the precise timing and details of the mechanisms
involved in the commitment of the two lineages remain
obscure. In this study, we demonstrate that the pre-GC phase
of effector CD4 T cell differentiation can be further divided into
two stages. In the first stage, viral-specific CD4 T cells differen-
tiate into either TCF1highBlimp1low TFH or TCF1
lowBlimp1high
Th1 cells. The two subsets expressed similar levels of
CXCR5 and both could be found in B cell follicles at this stage.
In the second stage, Th1 cells lost CXCR5 expression and
were now excluded from B cell follicles. Interestingly, early
TFH cells downregulated CD25 rapidly and expressed high
levels of Tcf7, closely resembling early memory precursor
CD8 T cells (Arsenio et al., 2014; Kalia et al., 2010). These cells
also have a transcriptional signature similar to memory precur-
sors (Choi et al., 2013). Of note, a subset of CXCR5+ memory
CD4 T cells have been found in the circulation of both human
and mice, reiterating a potential shared regulatory network be-
tween early viral-specific TFH cells and early memory precur-
sors (He et al., 2013; Locci et al., 2013). It is interesting to
speculate that TCF1 may be a component in this shared
signaling network, given its critical role in the development of
memory CD8 T cells (Zhou et al., 2010).tember 29, 2015 ª2015 The Authors 2107
Indeed, loss of TCF1 caused a profound defect in the TFH cell
response to viral infection, as shown here and by two other
recent studies (Choi et al., 2015; Xu et al., 2015). It is worth
noting, however, that, in our hands, the loss of TFH cells in
Tcf7-deficient SMARTA cells on day 3 p.i. was less dramatic
than that on day 8 p.i. It is possible that, while TCF1 is required
for optimal TFH cell responses prior to GC formation, a redundant
mechanism, such as the expression of the related transcription
factor LEF1, may compensate for Tcf7 deficiency during TFH dif-
ferentiation (Choi et al., 2015). However, we also found clear
evidence for both reduced proliferation and reduced cell survival
of TCF1-deficient TFH cells between day 3 and day 7 p.i., which is
a major part of the clonal expansion phase. Thus, TCF1 may be
required for the full expansion of TFH cells, which may account
for the differences in the extent of TFH defects between day 3
and day 8 p.i. It also should be noted that, although we have not
found evidence of conversion from Tcf7-deficient TFH cells to
Th1cells after tracking them for several days in infection-matched
mice, we did see a reduction in TFH gene expression and meta-
bolic signatures in the absence of TCF1. TCF1 also can suppress
expression of the Th1 cytokine IFNg. Thus, TCF1 may be critical
both for TFH expansion/survival and for the generation and main-
tenance of TFH identity in the face of strong Th1-inducing signals,
as seen in viral infections. In this respect, it is of interest that we
have not seen a requirement for TCF1 for TFH responses during
protein immunization with alum as an adjuvant, which is consid-
ered a Th2-inducing condition (T.W., unpublished data).
Previous studies have suggested that signaling mediated by
CD25 and Blimp1, which are abundantly expressed in early Th1
cells, inhibits TFH cell differentiation (Choi et al., 2011; Johnston
et al., 2012; Pepper et al., 2011). Our ChIP and gene expression
profiles of Tcf7-deficient TFH cells suggest that TCF1 potentially
represses expression of Prdm1 and Il2ra. Indeed, CD25
expression was lost much faster in TFH cells than in Th1 cells
early after infection. Given the high levels of TCF1 in TFH cells,
TCF1 may contribute to their rapid loss of CD25. Furthermore,
since IL-2 signaling increases CD25 expression, this could
amplify IL-2 signaling in Th1 cells, generating a positive feed-
back loop that may contribute to the difference in CD25
expression between the two subsets. It is of note that two
recent papers have found that loss of TCF1 or both TCF1
and LEF1 led to reduced Bcl6 as well as increased Blimp1
expression in TFH cells (Choi et al., 2015; Xu et al., 2015). While
we did not observe decreased Bcl6 expression, we did find that
overexpression of Bcl6 rescues TFH cell generation in the
absence of TCF1, confirming that TCF1 acts upstream of the
Blimp1/Bcl6 axes. Moreover, we found that TCF1 not only re-
presses Blimp1 and CD25 expression, but also is repressed
by Blimp1 and IL-2, suggesting that TCF1 is a critical compo-
nent of negative feedback loops with IL-2 and Blimp1 that
may regulate the differentiation and maintenance of TFH cells
during viral infections.
Upon antigen encounter, T cells switch from oxidative phos-
phorylation to aerobic glycolysis, a pattern that is enforced in
Th1 cells by IL-2 (MacIver et al., 2013; Oestreich et al., 2014).
However, the metabolic profile of TFH cells remains largely un-
known. We found that TFH cells have greater mitochondrial
mass than Th1 cells. An enhanced mitochondrial mass also2108 Cell Reports 12, 2099–2110, September 29, 2015 ª2015 The Awas observed in memory T cells, which is correlated with
elevated fatty acid oxidation (van derWindt et al., 2012). Interest-
ingly, our gene expression profiling data showed that Tcf7-defi-
cient TFH cells had reduced gene expression signatures related
to branched amino acid degradation, fatty acid degradation,
and the citrate cycle, suggesting reduced oxidative metabolism.
Consistent with these findings, the loss of TCF1 led to reduced
mitochondrial mass and function in TFH cells. Thus, TCF1 may
contribute to the regulation of TFH cell metabolism and promote
a more oxidative metabolic profile, although additional studies
will be necessary to determine potential targets of TCF1 that
contribute to these processes and whether they influence TFH
cell differentiation.
In summary, our study has demonstrated that the distinct high
levels of TCF1 expression distinguish TFH cells from Th1 cells
and are critical for the development of viral-specific TFH cells.
In addition, we have identified potential negative feedback loops
linking TCF1 to IL-2 and Blimp1. Our findings unveil an essential
role of TCF1 in contributing to the balance between immune re-
sponses mediated by two major CD4 subsets during viral infec-
tion and may help shed light on pathways important for the
development of vaccines and immune therapies targeting viral
infections.
EXPERIMENTAL PROCEDURES
Mice and Infections
Tcf7 conditional mice (Tcf7tm1a(EUCOMM)Wtsi, Institut Clinique de la Souris) were
crossed to Flp Deleter (7089, Taconic) and either CD4-Cre (Lee et al., 2001) or
ERT2-Cre (Seibler et al., 2003) (Taconic) to generate Tcf7loxP/loxP; CD4-Cre
(cKO) or Tcf7loxP/loxP; ERT2-Cre (iKO) mice, and to SMARTA transgenic
mice, expressing a TCR recognizing the LCMV GP66-77 epitope (Oxenius
et al., 1998). Blimp1-YFP mice (Fooksman et al., 2014) were crossed to
SMARTAmice. Other mouse strains, in vitro activation, retroviral transduction,
flow cytometry, microscopy, RNA and protein analyses, ChIP, and luciferase
assays are described in the Supplemental Experimental Procedures.
For adoptive transfers, 106 (for days 1.5, 2, and 3) or 104 (for other time
points) SMARTA CD4 T cells were transferred to recipient mice, unless indi-
cated. Mice were intravenously (i.v.) injected with 2 3 106 (for days 1.5, 2,
and 3) or 2 3 105 (for other time points) plaque-forming units (PFUs) of
LCMV Armstrong. For ERT2-Cre inducible KOs, 2 mg tamoxifen in corn oil
was injected intraperitoneally (i.p.) daily for 3–5 days before LCMV infection.
Controls were either Cre mice or mice transferred with ERT2-Cre SMARTA
injected with tamoxifen or ERT2-Cre+ animals injected with vehicle. All animal
husbandry and experiments were approved by the NHGRI or NINDS Animal
Use and Care Committees.
Statistical Analysis
Two-tailed paired or unpaired Student’s t test was performed with GraphPad
Prism 6 to calculate p values (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
0.0001).
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